Autobahn Therapeutics, a San Diego, CA-based developer of regenerative medicines to restore hope for people affected by CNS disorders, completed a $76m Series B funding round.
The round was co-led by Arch Venture Partners and Cowen Healthcare Investments, with participation from BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital and Alexandria Venture Investments.
The company intends to use the funds to advance its lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN), a rare genetic disorder, and a portfolio of transformational CNS programs leveraging its brain-targeting chemistry platform.
Led by Kevin Finney, chairman and chief executive officer, Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. The company is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder.
The company has built a team of experts in thyromimetics, drug discovery and development, clinical operations, and corporate and business development:
– Kevin Finney, chairman of the board of directors and chief executive officer;
– Keith Lenden, co-founder, president and chief operating officer;
– Brian Stearns, Ph.D., chief scientific officer;
– Chan Beals, M.D., Ph.D., senior vice president of translational medicine;
– Christine Maurer, senior vice president of development operations and program management;
– John Borkholder, J.D., general counsel and senior vice president of administration; and
– Thomas Scanlan, Ph.D., co-founder and senior advisor to Autobahn, and professor of Chemical Physiology and Biochemistry, Oregon Health & Science University.